CompanyOKYONasdaqLondon, X0

Okyo Pharma Ltd

OKYO Pharma develops urcosimod, a clinical-stage therapy for neuropathic corneal pain and anterior segment eye diseases.

SEC EDGAR ClinicalTrials.gov okyopharma.com

6-KSep 29Latest SEC filing

Sep 24Latest story

September 2026

Okyo registers Phase 3 trial of urcosimod for neuropathic corneal pain

Sep 24Trial updateOkyo Pharma Ltd urcosimod

Okyo Pharma to present at two European ophthalmology industry events in September 2026

Sep 9Clinical readoutOkyo Pharma Ltd urcosimod

July 2026

Okyo Pharma executives buy shares on Nasdaq over two days in July 2026

Jul 23PeopleOkyo Pharma Ltd

OKYO Pharma gets FDA Type D feedback, moves urcosimod into global Phase 3 for eye pain

Jul 8Clinical readoutOkyo Pharma Ltd urcosimod